<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01485861</url>
  </required_header>
  <id_info>
    <org_study_id>GO27983</org_study_id>
    <secondary_id>2011-004126-10</secondary_id>
    <nct_id>NCT01485861</nct_id>
  </id_info>
  <brief_title>Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy</brief_title>
  <official_title>A Phase Ib/II Study of Ipatasertib (GDC-0068) or Apitolisib (GDC-0980) With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This multicenter, international, Phase Ib/II trial consists of three stages: a Phase Ib,
      open-label stage in which the recommended Phase II dose was determined for ipataseritib
      administrated in combination with abiraterone and of GDC-0980 administrated in combination
      with abiraterone (this phase is no longer active), a Phase II, 3-arm, double-blind,
      randomized comparison of ipatasertib with abiraterone and prednisone/prednisolone versus
      placebo with abiraterone and prednisone/prednisolone and a safety single-arm, open-label
      cohort of ipatasertib 400 mg daily alone or in combination with prednisone/prednisolone or
      prednisone/prednisolone plus abiraterone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2012</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib: Percentage of Participants With Dose Limiting Toxicity (DLTs)</measure>
    <time_frame>Days 1 to 28 of Cycle 1 (Cycle length = 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Percentage of Participants by Nature of DLTs</measure>
    <time_frame>Days 1 to 28 of Cycle 1 (Cycle length = 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Recommended Phase II Dose (RP2D) of Ipatasertib</measure>
    <time_frame>Days 1 to 28 of Cycle 1 (Cycle length = 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Percentage of Participants With Radiographic Progression (as Assessed by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) or Death - Intent to Treat (ITT) Population</measure>
    <time_frame>Screening up to radiographic progression or death, whichever occurs first (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter, and at treatment completion [up to 3.6 years overall]) (cycle length = 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Radiographic Progression Free Survival as Assessed by RECIST 1.1 - ITT Population</measure>
    <time_frame>Screening up to radiographic progression or death, whichever occurs first (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter, and at treatment completion [up to 3.6 years overall]) (cycle length = 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Percentage of Participants With Radiographic Progression (as Assessed by RECIST 1.1) or Death in Participants With Institute of Cancer Research (ICR) Phosphatase and Tensin Homolog (PTEN) Loss</measure>
    <time_frame>Screening up to radiographic progression or death, whichever occurs first (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter, and at treatment completion [up to 3.6 years overall]) (cycle length = 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Radiographic Progression Free Survival (as Assessed by RECIST 1.1) in Participants With ICR PTEN Loss</measure>
    <time_frame>Screening up to radiographic progression or death, whichever occurs first (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter, and at treatment completion [up to 3.6 years overall]) (cycle length = 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Percentage of Participants with AEs, graded according to the NCI CTCAE v4.0</measure>
    <time_frame>Baseline to Treatment Completion (Up to 3.6 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants Who Died - ITT Population</measure>
    <time_frame>Screening up to death (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Overall Survival - ITT Population</measure>
    <time_frame>Screening up to death (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants Who Died in Participants With ICR PTEN Loss</measure>
    <time_frame>Screening up to death (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Overall Survival in Participants With ICR PTEN Loss</measure>
    <time_frame>Screening up to death (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With Prostate-Specific Antigen (PSA) Progression (as Assessed by Prostate Cancer Working Group 2 Criteria) - ITT Population</measure>
    <time_frame>Screening up to PSA progression (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Time to PSA Progression (as Assessed by Prostate Cancer Working Group 2 Criteria) - ITT Population</measure>
    <time_frame>Screening up to PSA progression (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With PSA Progression (as Assessed by Prostate Cancer Working Group 2 Criteria) in Participants With ICR PTEN Loss</measure>
    <time_frame>Screening up to PSA progression (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Time to PSA Progression (as Assessed by Prostate Cancer Working Group 2 Criteria) in Participants With ICR PTEN Loss</measure>
    <time_frame>Screening up to PSA progression (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With PSA Response - ITT Population</measure>
    <time_frame>Baseline, Day 1 of every cycle (starting from Cycle 2) till 30 days after last dose (up to overall 3.6 years) (cycle length = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With PSA Response in Participants With ICR PTEN Loss</measure>
    <time_frame>Baseline, Day 1 of every cycle (starting from Cycle 2) till 30 days after last dose (up to overall 3.6 years) (cycle length = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With Objective Response as Assessed by RECIST 1.1 - ITT Population</measure>
    <time_frame>Screening up to radiographic progression or death, whichever occurred first (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With Objective Response (as Assessed by RECIST 1.1) in Participants With ICR PTEN Loss</measure>
    <time_frame>Screening up to radiographic progression or death, whichever occurred first (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Duration of Tumor Response, as Assessed by RECIST 1.1 - ITT Population</measure>
    <time_frame>Screening up to radiographic progression or death, whichever occurred first (assessed at screening, after Cycles 3, 5, 7, 9, every three cycles [12 weeks] thereafter up to end of treatment [up to 3.6 years overall]) (cycle length = 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With Circulating Tumor Cells (CTC) Reduction Response - ITT Population</measure>
    <time_frame>Screening, on Day 1 of Cycle 2, on Day 1 of Cycle 3, and at the treatment completion visit (up to overall 3.6 years) (cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With CTC Reduction Response in Participants With ICR PTEN Loss</measure>
    <time_frame>Baseline, on Day 1 of Cycle 2, on Day 1 of Cycle 3, and at the treatment completion visit (up to overall 3.6 years) (cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With CTC Conversion - ITT Population</measure>
    <time_frame>Baseline, on Day 1 of Cycle 2, on Day 1 of Cycle 3, and at the treatment completion visit (up to overall 3.6 years) (cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With CTC Conversion in Participants With ICR PTEN Loss</measure>
    <time_frame>Baseline, on Day 1 of Cycle 2, on Day 1 of Cycle 3, and at the treatment completion visit (up to overall 3.6 years) (cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With Pain Progression - ITT Population</measure>
    <time_frame>Screening, Day 1 of each cycle (cycle length=28 days) up to treatment completion (up to 3.6 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Time to Pain Progression - ITT Population</measure>
    <time_frame>Screening, Day 1 of each cycle (cycle length=28 days) up to treatment completion (up to 3.6 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With Pain Progression in Participants With ICR PTEN Loss</measure>
    <time_frame>Screening, Day 1 of each cycle (cycle length=28 days) up to treatment completion (up to 3.6 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Time to Pain Progression in Participants With ICR PTEN Loss</measure>
    <time_frame>Screening, Day 1 of each cycle (cycle length=28 days) up to treatment completion (up to 3.6 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Maximum Plasma Concentration (Cmax) (in nanograms per milliliter [ng/mL]) of Ipatasertib and Apitolisib When Co-Administered With Abiraterone</measure>
    <time_frame>Predose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Time to Cmax (tmax) (in hours) of Ipatasertib and Apitolisib When Co-Administered With Abiraterone</measure>
    <time_frame>Predose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Area Under The Concentration Time Curve From Time 0 to 24 Hours (AUC0-24) (in ng/mL*hours) of Ipatasertib and Apitolisib When Co-Administered With Abiraterone</measure>
    <time_frame>Predose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Total Body Clearance (CL/F) of Ipatasertib When Co-Administered With Abiraterone</measure>
    <time_frame>Predose (0 hour), 1, 2, 4, 6, 24 hours post dose on Day 15 of Cycle 1 (cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Accumulation Ratio of Ipatasertib When Co-Administered With Abiraterone</measure>
    <time_frame>Predose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of G-037720 (Metabolite of Ipatasertib)</measure>
    <time_frame>Predose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax of G-037720 (Metabolite of Ipatasertib)</measure>
    <time_frame>Predose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: AUC0-24 of G-037720 (Metabolite of Ipatasertib)</measure>
    <time_frame>Predose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Accumulation Ratio of G-037720 (Metabolite of Ipatasertib)</measure>
    <time_frame>Predose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Cmax of Abiraterone When Co-Administered With Ipatasertib or Apitolisib</measure>
    <time_frame>Predose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: tmax of Abiraterone When Co-Administered With Ipatasertib or Apitolisib</measure>
    <time_frame>Predose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: AUC0-24 of Abiraterone When Co-Administered With Ipatasertib or Apitolisib</measure>
    <time_frame>Predose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Plasma Half-Life of Abiraterone When Co-Administered With Ipatasertib or Apitolisib</measure>
    <time_frame>Predose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Accumulation Ratio of Abiraterone When Co-Administered With Ipatasertib or Apitolisib</measure>
    <time_frame>Predose (0 hour), 1, 2, 4, 6, 24 hours post dose on Days 1, 15 of Cycle 1 (cycle length=28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Cohort: Percentage of Participants with AEs, Graded According to the NCI CTCAE v4.0</measure>
    <time_frame>Day -1 of Cycle 1 to Day 1 of Cycle 2 (cycle length=25 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Cohort: Comparing of Average and Peak Glucose over 24h by CGM for Participants Receiving Ipataseritib+Prednisone+Abiraterone with AM Dosing of Ipatasertib</measure>
    <time_frame>Day -1 of Cycle 1 to Day 1 of Cycle 2 (cycle lenght=25 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Cohort: Comparing of Average and Peak Glucose over 24h by CGM for Participants Receiving Ipataseritib+Prednisone+Abiraterone with PM Dosing of Ipatasertib</measure>
    <time_frame>Day -1 of Cycle 1 to Day 1 of Cycle 2 (cycle lenght=25 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Cohort: Comparing of Average and Peak Glucose Over 24h by CGM for Participants Receiving Ipatasertib Alone</measure>
    <time_frame>Day -1 of Cycle 1 to Day 1 of Cycle 2 (cycle lenght=25 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Cohort: Comparing of Average and Peak Glucose Over 24h by CGM for Participants Receiving Ipatasertib+Prednisone</measure>
    <time_frame>Day -1 of Cycle 1 to Day 1 of Cycle 2 (cycle lenght=25 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Cohort: Comparing of Average and Peak Glucose Over 24h by CGM for Participants Receiving Ipatasertib+Prednisone+Abiraterone</measure>
    <time_frame>Day -1 of Cycle 1 to Day 1 of Cycle 2 (cycle lenght=25 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">295</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Phase Ib: Ipatasertib 400 mg + abiraterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ipatasertib 400 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg twice daily (bid) continuously in 28-day treatment cycles until disease progression or intolerable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ib: Apitolisib 30 mg + abiraterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive apitolisib 30 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg twice daily (bid) continuously in 28-day treatment cycles until disease progression or intolerable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Ipatasertib 400 mg + abiraterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Ipatasertib 400 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Ipatasertib 200 mg + abiraterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Ipatasertib 200 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Placebo + abiraterone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo (for Ipatasertib) once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safety Cohort: Ipataseritib 400 mg + Abiraterone + Prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Ipataseritib 400 mg once daily in the AM for Cycle 1 day 1-18. On Day 19, Ipataseritib 400 mg will be switched to PM dosing for the remainder of the Cycle 1.
Prednisone 5 mg starts in the PM of Cycle 1 day 8 and taken BID thereafter for the remainder of the study treatment Abiraterone 1000mg once a day starts on Cycle1 day 12 in the AM and should be taken at the same time as Ipataseritib. Starting from cycle 1 day 19, Ipataseritib and Abiraterone are dosed in PM at should be taken together at the same time each day until cycle 2 day 1. Starting from Cycle 2 Day 1, Participants may choose to take Ipatasertib and Abiraterone in either the AM or PM; however, they should be taken together at approximately the same time each day.
Participants will receive the study treatment until disease progression or intolerable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>Orally once daily</description>
    <arm_group_label>Phase II: Ipatasertib 200 mg + abiraterone</arm_group_label>
    <arm_group_label>Phase II: Ipatasertib 400 mg + abiraterone</arm_group_label>
    <arm_group_label>Phase II: Placebo + abiraterone</arm_group_label>
    <arm_group_label>Phase Ib: Apitolisib 30 mg + abiraterone</arm_group_label>
    <arm_group_label>Phase Ib: Ipatasertib 400 mg + abiraterone</arm_group_label>
    <arm_group_label>Safety Cohort: Ipataseritib 400 mg + Abiraterone + Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apitolisib</intervention_name>
    <description>Orally once daily</description>
    <arm_group_label>Phase Ib: Apitolisib 30 mg + abiraterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipatasertib</intervention_name>
    <description>Orally once daily</description>
    <arm_group_label>Phase II: Ipatasertib 200 mg + abiraterone</arm_group_label>
    <arm_group_label>Phase II: Ipatasertib 400 mg + abiraterone</arm_group_label>
    <arm_group_label>Phase Ib: Ipatasertib 400 mg + abiraterone</arm_group_label>
    <arm_group_label>Safety Cohort: Ipataseritib 400 mg + Abiraterone + Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Orally once daily</description>
    <arm_group_label>Phase II: Placebo + abiraterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Orally bid</description>
    <arm_group_label>Phase II: Ipatasertib 200 mg + abiraterone</arm_group_label>
    <arm_group_label>Phase II: Ipatasertib 400 mg + abiraterone</arm_group_label>
    <arm_group_label>Phase II: Placebo + abiraterone</arm_group_label>
    <arm_group_label>Phase Ib: Apitolisib 30 mg + abiraterone</arm_group_label>
    <arm_group_label>Phase Ib: Ipatasertib 400 mg + abiraterone</arm_group_label>
    <arm_group_label>Safety Cohort: Ipataseritib 400 mg + Abiraterone + Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Orally bid</description>
    <arm_group_label>Phase II: Ipatasertib 200 mg + abiraterone</arm_group_label>
    <arm_group_label>Phase II: Ipatasertib 400 mg + abiraterone</arm_group_label>
    <arm_group_label>Phase II: Placebo + abiraterone</arm_group_label>
    <arm_group_label>Phase Ib: Apitolisib 30 mg + abiraterone</arm_group_label>
    <arm_group_label>Phase Ib: Ipatasertib 400 mg + abiraterone</arm_group_label>
    <arm_group_label>Safety Cohort: Ipataseritib 400 mg + Abiraterone + Prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed metastatic or advanced prostate adenocarcinoma that has been
             previously treated with docetaxel-based therapy and has progressed during treatment of
             at least one hormonal therapy(prior docetaxel is not required for the safety cohort)

          -  Two rising PSA levels greater than or equal to (&gt;/=) 2 ng/mL measured &gt;/= 1 week apart
             or radiographic evidence of disease progression in soft tissue or bone

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening

          -  Adequate hematologic and organ function

          -  Documented willingness to use an effective means of contraception

          -  Safety cohort only: agreement to use CGM for first cycle of treatment

        Exclusion Criteria:

          -  History of Type I or Type II diabetes mellitus requiring insulin; safety cohort:
             patients who are receiving any pharmacologic treatment for diabetes are not eligible

          -  New York Heart Association Class III or IV heart failure or Left ventricular ejection
             fraction &lt; 50% or ventricular arrhythmia requiring medication

          -  Significant atherosclerotic disease, as evidenced by: unstable angina, history of
             myocardial infarction within 6 months prior to Day 1, or cerebrovascular accident
             within 6 months prior to Day 1

          -  Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory
             drugs or active inflammatory disease which requires immunosuppressive therapy

          -  Clinically significant history of liver disease

          -  History of adrenal insufficiency or hyperaldosteronism

          -  Phase II only: Previous therapy for prostate cancer with 17
             alpha-hydroxylase/C17,20-lyase inhibitors, including abiraterone

          -  Phase II only: Previous treatment for prostate cancer with Protein kinase B
             phosphatidylinositol 3 kinase and/or mammalian target of rapamycin inhibitors

          -  Need for chronic corticosteroid therapy of &gt;/= 20 mg of prednisone per day or an
             equivalent dose of other anti inflammatory corticosteroids or immunosuppressant
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO27983 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth Research Institute - Bisgrove</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Pacific Hematology Oncology Assocociates</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - Fort Myers (New Hampshire Ct)</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901-8101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists.</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists; Sarasota</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Ctr</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Univ; Bunting Blaustein Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Urology Cancer Center &amp; GU Research Network</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Cancer and Blood Specialists - Setauket Medical Oncology</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center - Tennessee Oncology, Pllc</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Masarykuv onkologicky ustav</name>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove; I. interni klinika,Oddeleni invazivni kardiologie</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50012</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Urocentrum Praha s.r.o.</name>
      <address>
        <city>Praha 2</city>
        <zip>120 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Fakultni Thomayerova Nemocnice; Revmatologicke Oddeleni</name>
      <address>
        <city>Praha</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>ICO Paul Papin; Oncologie Medicale.</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard - Centre régional de lutte contre le cancer Rhône-Alpes</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hia Du Val De Grace</name>
      <address>
        <city>Paris</city>
        <zip>75230</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie; Oncologie Medicale</name>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GH Paris Saint Joseph; Hopital De Jour Oncologie</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hopital d'Instruction des Armees de Begin</name>
      <address>
        <city>Saint-Mande</city>
        <zip>94160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy; Departement Oncologie Medicale</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Alexandras Hospital; Dept. of Clin. Therapeutics, Athens Uni School of Medicine</name>
      <address>
        <city>Athens</city>
        <zip>115 28</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Univ General Hosp Heraklion; Medical Oncology</name>
      <address>
        <city>Heraklion</city>
        <zip>711 10</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patras Medical Oncology</name>
      <address>
        <city>Patras</city>
        <zip>265 04</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital; 2Nd Oncology Clinic</name>
      <address>
        <city>Piraeus</city>
        <zip>185 47</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Larissa; Oncology</name>
      <address>
        <city>Λαρισα</city>
        <zip>413 35</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica</name>
      <address>
        <city>Meldola</city>
        <state>Emilia-Romagna</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Camillo Forlanini; Oncologia Medica</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Istituti Ospitalieri</name>
      <address>
        <city>Cremona</city>
        <state>Lombardia</state>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Irccs Ospedale San Raffaele;Oncologia Medica</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Donato; Divisione Di Reumatologia</name>
      <address>
        <city>Arezzo</city>
        <state>Toscana</state>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Het Nederlands Kanker Inst</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 EC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Vu Medisch Centrum; Afdeling Longziekten</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>MC Haaglanden; Oncologie</name>
      <address>
        <city>Den Haag</city>
        <zip>2512 VA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>UMC St Radboud</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sint Franciscus Gasthuis; Inwendige Geneeskunde</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sf. Constantin Hospital; Oncology</name>
      <address>
        <city>Brasov</city>
        <zip>500019</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. Th. Burghele Clin Urology Hosp</name>
      <address>
        <city>Bucharest</city>
        <zip>050659</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. I. Chiricuta Institute of Oncology</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology &quot;Prof. Dr. I. Chiricuta&quot;</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ONCOMED - Medical Centre</name>
      <address>
        <city>Timisoara</city>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Municipal Hosp Turdal; Oncology</name>
      <address>
        <city>Turda</city>
        <zip>401103</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche; Servicio de Oncologia</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli; Servicio de Oncologia</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Vall d'Hebron; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Madrid Norte Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital; Centre for Clinical Haematology</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0XH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St. James University Hospital; Pharmacy Department</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Centre NHS Foundation Trust</name>
      <address>
        <city>Wirral</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 2, 2011</study_first_submitted>
  <study_first_submitted_qc>December 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2011</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

